Thermo Fisher Scientific is now offering €43 per QGEN share, up from the previous €39 per share offer, at the same time that the companies have agreed to reduce the minimum acceptance threshold to 66.67% from the previous 75%. The deal remains valued at about $11.5 billion.
Shareholders in recent weeks had questioned the original per share offer, with Hedge Fund Davidson Kempner calling the offer “wholly inadequate,” according to Reuters.
Both companies’ boards have approved the acquisition.
Qiagen in March received an FDA emergency use authorization for a COVID-19 diagnostic test.